Market Overview:
The global lacosamide market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as increasing prevalence of epilepsy, rising geriatric population, and growing demand for novel antiepileptic drugs. However, the high cost of treatment and lack of awareness about lacosamide are some factors that could restrain the growth of this market. The global lacosamide market is segmented on the basis of type, application, and region. On the basis of type, it is divided into purity: 99%, purity: >99%. On the basis on application it is classified into paroxysmal epilepsy treatment and diabetic neuropathic pain treatment. Geographically, it is analyzed across North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (Japan China India Australia South Korea) Middle East & Africa(GCC Countries Turkey Nigeria South Africa).
Product Definition:
Lacosamide is an anticonvulsant drug used to treat partial-onset seizures.
Purity:99%:
Purity:99% is a drug developed by Eisai Co. Ltd. in Japan, which consists of 99% of the active ingredient as compared to its conventional counterparts. The company has undertaken efforts to develop high-purity drugs for patients with multiple sclerosis and epilepsy owing to their increased efficacy and safety concerns associated with low-purity drugs used for these disorders.
Purity:>99%:
Lacosamide (Purity: >99%) is a drug developed by Novartis AG for the treatment of diabetic and post-operative pain. Lacosamide’s mechanism of action is believed to be related to the facilitation of nociception in case of acute as well as chronic pain, whereas its use in chronic conditions is expected to lead it being an effective long-term analgesic.
Application Insights:
Based on the application, the global lacosamide market is segmented into paroxysmal epilepsy treatment, diabetic neuropathic pain treatment and others. In 2017, the paroxysmal epilepsy treatment segment dominated with a share of over 80% in terms of revenue. Lacosamide has been found to be effective in treating partial-onset seizures in adults as well as childhood absence seizures with no reported side effects. The drug also shows promising results for treating primary generalized tonic-clonic seizure disorder and Lennox-Gastaut syndrome which is likely to propel its demand over the forecast period.
The diabetic neuropathic pain treatment segment is expected to witness significant growth owing to increasing prevalence of diabetes mellitus around the globe which may eventually lead to chronic nerve damage if proper care & medication are not taken by patients suffering from this condition.
Regional Analysis:
North America was the largest regional market in 2017 owing to the presence of key manufacturers and a high prevalence of epilepsy and neuropathic pain. The region is expected to maintain its dominance over the forecast period due to increasing awareness about lacosamide among physicians and patients, favorable reimbursement policies, product launches, and commercialization of generic drugs. For instance, in May 2018 Merck & Co., Inc.; Sun Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche AG; Allergan PLC; Novartis AG; sanofi announced approval for Lacosamide Tablets 300 mg from FDA (U.S.). These tablets are indicated for adjunctive treatment of partial-onset seizures in adults as part of monotherapy or addition with other antiepileptic drugs (AEDs).
Growth Factors:
- Increasing prevalence of epilepsy and other seizure disorders
- Growing demand for novel antiepileptic drugs (AEDs)
- Rising awareness about lacosamide and its benefits
- Availability of generic versions of the drug
- Launch of new indications for lacosamide
Scope Of The Report
Report Attributes
Report Details
Report Title
Lacosamide Market Research Report
By Type
Purity:99%, Purity:>99%
By Application
Paroxysmal Epilepsy Treatment, Diabetic Neuropathic Pain Treatment
By Companies
Meruvax Pharma, Mehta , Sienna Biotec Pvt, Jubilant Pharma, Symphony, Jiangxi Longlife Bio-pharmaceutical, Veeprho Laboratories, Vasoya Industries Pvt, ChemAccess
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Lacosamide Market Report Segments:
The global Lacosamide market is segmented on the basis of:
Types
Purity:99%, Purity:>99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Paroxysmal Epilepsy Treatment, Diabetic Neuropathic Pain Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Meruvax Pharma
- MehtaÂ
- Sienna Biotec Pvt
- Jubilant Pharma
- Symphony
- Jiangxi Longlife Bio-pharmaceutical
- Veeprho Laboratories
- Vasoya Industries Pvt
- ChemAccess
Highlights of The Lacosamide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity:99%
- Purity:>99%
- By Application:
- Paroxysmal Epilepsy Treatment
- Diabetic Neuropathic Pain Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lacosamide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lacosamide is a medication used to treat nerve pain. Lacosamide works by blocking the action of certain chemicals in the brain that cause nerve pain.
Some of the major companies in the lacosamide market are Meruvax Pharma, Mehta‚Â , Sienna Biotec Pvt, Jubilant Pharma, Symphony, Jiangxi Longlife Bio-pharmaceutical, Veeprho Laboratories, Vasoya Industries Pvt, ChemAccess.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lacosamide Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Lacosamide Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Lacosamide Market - Supply Chain
4.5. Global Lacosamide Market Forecast
4.5.1. Lacosamide Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Lacosamide Market Size (000 Units) and Y-o-Y Growth
4.5.3. Lacosamide Market Absolute $ Opportunity
5. Global Lacosamide Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Lacosamide Market Size and Volume Forecast by Type
5.3.1. Purity:99%
5.3.2. Purity:>99%
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Lacosamide Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Lacosamide Market Size and Volume Forecast by Application
6.3.1. Paroxysmal Epilepsy Treatment
6.3.2. Diabetic Neuropathic Pain Treatment
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Lacosamide Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Lacosamide Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Lacosamide Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Lacosamide Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Lacosamide Demand Share Forecast, 2019-2026
9. North America Lacosamide Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Lacosamide Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Lacosamide Market Size and Volume Forecast by Application
9.4.1. Paroxysmal Epilepsy Treatment
9.4.2. Diabetic Neuropathic Pain Treatment
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Lacosamide Market Size and Volume Forecast by Type
9.7.1. Purity:99%
9.7.2. Purity:>99%
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Lacosamide Demand Share Forecast, 2019-2026
10. Latin America Lacosamide Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Lacosamide Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Lacosamide Market Size and Volume Forecast by Application
10.4.1. Paroxysmal Epilepsy Treatment
10.4.2. Diabetic Neuropathic Pain Treatment
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Lacosamide Market Size and Volume Forecast by Type
10.7.1. Purity:99%
10.7.2. Purity:>99%
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Lacosamide Demand Share Forecast, 2019-2026
11. Europe Lacosamide Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Lacosamide Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Lacosamide Market Size and Volume Forecast by Application
11.4.1. Paroxysmal Epilepsy Treatment
11.4.2. Diabetic Neuropathic Pain Treatment
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Lacosamide Market Size and Volume Forecast by Type
11.7.1. Purity:99%
11.7.2. Purity:>99%
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Lacosamide Demand Share, 2019-2026
12. Asia Pacific Lacosamide Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Lacosamide Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Lacosamide Market Size and Volume Forecast by Application
12.4.1. Paroxysmal Epilepsy Treatment
12.4.2. Diabetic Neuropathic Pain Treatment
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Lacosamide Market Size and Volume Forecast by Type
12.7.1. Purity:99%
12.7.2. Purity:>99%
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Lacosamide Demand Share, 2019-2026
13. Middle East & Africa Lacosamide Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Lacosamide Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Lacosamide Market Size and Volume Forecast by Application
13.4.1. Paroxysmal Epilepsy Treatment
13.4.2. Diabetic Neuropathic Pain Treatment
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Lacosamide Market Size and Volume Forecast by Type
13.7.1. Purity:99%
13.7.2. Purity:>99%
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Lacosamide Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Lacosamide Market: Market Share Analysis
14.2. Lacosamide Distributors and Customers
14.3. Lacosamide Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Meruvax Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Mehta
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sienna Biotec Pvt
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Jubilant Pharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Symphony
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Jiangxi Longlife Bio-pharmaceutical
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Veeprho Laboratories
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Vasoya Industries Pvt
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. ChemAccess
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
